[Behçet's disease].
Kitaichi
Nobuyoshi
N
Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine.
Ohno
Shigeaki
S
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000737:chemistry; D001323:Autoantibodies; D001528:Behcet Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D003078:Colchicine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D015235:HLA-B Antigens; D059949:HLA-B51 Antigen; D006360:Heat-Shock Proteins; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D018716:Molecular Mimicry; D013298:Streptococcus sanguis / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001323:Autoantibodies; D005938:Glucocorticoids; D015235:HLA-B Antigens; D059949:HLA-B51 Antigen; D006360:Heat-Shock Proteins; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D000069285:Infliximab; D003078:Colchicine